Methods and compositions using crosslinked aliphatic polyesters in well bore applications

Information

  • Patent Grant
  • 7833944
  • Patent Number
    7,833,944
  • Date Filed
    Thursday, June 18, 2009
    15 years ago
  • Date Issued
    Tuesday, November 16, 2010
    14 years ago
Abstract
Methods and compositions including a method comprising: providing a treatment fluid comprising a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester; and placing the treatment fluid into a subterranean formation.
Description
BACKGROUND

The present invention relates to crosslinked aliphatic polyesters and, more particularly, in certain embodiments, to methods and compositions that use crosslinked aliphatic polyesters in well bore applications, particularly in high-temperature applications.


Aliphatic polyesters are commonly employed in well bore applications. For instance, aliphatic polyesters may be used in subterranean operations as fluid loss control particles, diverting agents, bridging agents, drilling fluid additives, cement additives, and the like. In another instance, the aliphatic polyesters may be capable of releasing a desirable degradation product, e.g., an acid, during its hydrolysis. The acid released by certain aliphatic polyesters may be used to facilitate a reduction in viscosity of a fluid or to degrade a filter cake, as well as for numerous other functions in subterranean operations.


Inclusion of an aliphatic polyester capable of releasing an acid in a gelled (and optionally crosslinked) treatment fluid may be used to facilitate a reduction in viscosity of such fluid. Generally, these aliphatic polyesters likely will hydrolyze over time due to contact with water present in the fluid, thereby releasing an acid. Upon its hydrolysis, the acid will function, inter alia, to reduce the crosslinks in the treatment fluid, reducing the pH of the treatment fluid sufficiently to reverse the crosslinks therein, and/or breaking down the backbone of the gelling agent present in the treatment fluid. Typically, the acid released by the aliphatic polyester may breakdown the gelling agents, and this phenomena may be accelerated at elevated temperatures such as those above about 150° F.


Aliphatic polyesters capable of releasing an acid may also be used in the degradation of acid-soluble materials present in a subterranean formation, such as those present in or adjacent to filter cakes. Filter cakes commonly may be formed by a fluid (e.g., a treatment fluid) on the face of a portion of a subterranean formation, inter alia, to minimize damage to the permeability thereof. The filter cake often comprises an acid-soluble component (e.g., a calcium carbonate bridging agent) and a polymeric component (e.g., starch and xanthan). Before desirable fluids, such as hydrocarbons, may be produced, the filter cake is generally removed. To facilitate the degradation of the acid-soluble component, an aliphatic polyester capable of releasing an acid may be utilized. Filter cakes also may be removed using an acid where the filter cake does not contain an acid-soluble component, for example, by degrading the underlying carbonate adjacent to the filter cake, if the filter cake is present in a carbonate formation.


In one instance, the filter cake may be contacted by a treatment fluid that comprises the aliphatic polyester. The resultant acid should interact with the acid-soluble component of the filter cake and/or the underlying carbonate adjacent to the filter cake in such a way as to facilitate their degradation. In another instance, the aliphatic polyester capable of releasing an acid may be included in the fluid (such as the treatment fluid) that forms the filter cake, such that the filter cake further contains the aliphatic polyester. Subsequent contact of the filter cake with an aqueous fluid hydrolyzes the water-hydrolysable material thereby releasing an acid that acts to degrade the acid soluble component of the filter cake. Among other components, the aqueous fluid may contain oxidizing agents or enzymes suitable to facilitate the degradation of the polymeric component of the filter cake.


The use of aliphatic polyesters may be problematic in high-temperature wells. At higher temperatures, such as those above about 300° F., the use of aliphatic polyesters in subterranean formations may not be suitable. At such temperatures, the presence of aqueous fluids could lead to early hydrolysis of the aliphatic polyesters. Similarly the use of crystalline aliphatic polyesters or stereoisomers may also be problematic in high-temperature wells.


SUMMARY

The present invention relates to crosslinked aliphatic polyesters and, more particularly, in certain embodiments, to methods and compositions that use crosslinked aliphatic polyesters in well bore applications, particularly in high-temperature applications.


In one embodiment, the present invention comprises a method comprising: providing a treatment fluid comprising a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester; and placing the treatment fluid into a subterranean formation.


In another embodiment, the present invention comprises a method comprising: placing a treatment fluid in a subterranean formation, the treatment fluid comprising: a carrier fluid; a viscosifier; a fluid loss control additive; and a bridging agent comprising a crosslinked aliphatic polyester; and forming a filter cake comprising the bridging agent upon a surface within the subterranean formation whereby fluid loss to the subterranean formation through the filter cake is reduced.


In another embodiment, the present invention comprises a treatment fluid comprising a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester.


The features and advantages of the present invention will be readily apparent to those skilled in the art. While numerous changes may be made by those skilled in the art, such changes are within the spirit of the invention.







DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention relates to crosslinked aliphatic polyesters and, more particularly, in certain embodiments, to methods and compositions that use crosslinked aliphatic polyesters in well bore applications, particularly in high-temperature applications.


There may be several potential advantages to the methods and compositions of the present invention. One of the many potential advantages of the methods and compositions of the present invention is that they may allow for, inter alia, higher temperature use in subterranean formations than methods and compositions that use uncrosslinked aliphatic polyesters. Another potential advantage of the methods and compositions of the present invention is that they may allow use in subterranean formations where longer degradation times are needed at higher temperatures, such as for use as diverting particles, filter cakes, fluid loss control additives, drill in fluids, or bridging agents. Methods of treating subterranean formations are described in U.S. Patent Application Publication Nos. 2007/0078064, 2005/0059556, and 2005/0059557, the entireties of which are herein incorporated by reference. Another potential advantage of the methods and compositions of the present invention is that crosslinking may also increase the heat stability of polyesters above the Tg and also increase the melting point of the polymer. In some instances it may be desirable for the polyesters to retain some of their solid particle properties past the Tg, Tc, or Tm of the aliphatic polyester.


Embodiments of the treatment fluids of the present invention generally comprise a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester. The carrier fluid utilized in embodiments of the treatment fluids of the present invention may be aqueous-based, nonaqueous-based, or mixtures thereof. Where the carrier fluid is aqueous-based, the water used may be fresh water, salt water (e.g., water containing one or more salts dissolved therein), brine (e.g., saturated salt water), or seawater. Generally, the water may be from any source, provided that it does not contain an excess of compounds that may adversely affect other components in the treatment fluid. Where the carrier fluid is nonaqueous-based, the carrier fluid may comprise any number of organic fluids. Examples of suitable organic fluids include, but are not limited to, mineral oils, synthetic oils, esters and the like. These organic fluids may be referred to generically as “oils.” Generally, any oil in which a water solution of salts can be emulsified may be suitable for use as a carrier fluid in the treatment fluids of the present invention. Generally, the carrier fluid may be present in embodiments of the treatment fluids of the present invention in an amount in the range of about 20% to about 99% by weight of the treatment fluid. In certain embodiments, the carrier fluid may be present in the treatment fluids of the present invention in an amount in the range of about 20% to about 80% by weight of the treatment fluid.


The solid particle that comprises the crosslinked aliphatic polyester may be included in the treatment fluids of the present invention in an amount sufficient for a particular application. In certain embodiments, the solid particle may be present in an amount in the range of about 0.1% to about 32% by weight of the treatment fluid. In certain embodiments, the solid particle may be present in an amount of about 1% to about 10% by weight of the treatment fluid.


The specific features of the solid particle may be modified based on the particular application. For example, where used in forming a filter cake, the specific features of the solid particle may be modified so as to maintain the filter cake's filtering capability when the filter cake is intact while easing the removal of the filter cake when such removal becomes desirable. In certain embodiments, the solid particle may have a particle size distribution in the range of about 0.1 micron to about 1.0 millimeters. Furthermore, the solid particle may have any suitable shape, including, but not limited to, particles having the physical shape of platelets, shavings, flakes, ribbons, rods, strips, spheroids, toroids, pellets, tablets, or any other physical shape. One of ordinary skill in the art with the benefit of this disclosure will recognize the appropriate size and shape for a given application.


As previously mentioned, the solid particles included in embodiments of the treatment fluids may comprise a crosslinked aliphatic polyester. Suitable crosslinked aliphatic polyesters for use in embodiments of the present invention include those formed by crosslinking aliphatic polyesters having the general formula of repeating units shown below:




embedded image



where n is an integer between 75 and 10,000 and R is a hydrogen, alkyl, aryl, alkylaryl, acetyl, heteroatoms, or mixtures thereof. Of these aliphatic polyesters, poly(lactic acid) is preferred. Poly(lactic acid) is synthesized either from lactic acid by a condensation reaction or more commonly by ring-opening polymerization of a cyclic lactide monomer. Since both lactic acid and lactide can achieve the same repeating unit, the general term poly(lactic acid), as used herein, refers to Formula I without any limitation as to how the polymer was made, such as from lactides, lactic acid, or oligomers, and without reference to the degree of polymerization or level of plasticization. The lactide monomer exists generally in three different forms: two stereoisomers L- and D-lactide and racemic D,L-lactide (meso-lactide). The oligomers of lactic acid and oligomers of lactide are defined by the formula:




embedded image



where m is an integer 2≦m≦75. Preferably m is an integer and 2≦m≦10. These limits correspond to number average molecular weights below about 5,400 and below about 720, respectively. The chirality of the lactide units provides a means to adjust, inter alia, degradation rates, as well as physical and mechanical properties. Poly(L-lactide), for instance, is a semicrystalline polymer with a relatively slow hydrolysis rate. The use of poly(L-lactide) could be desirable in applications of the present invention where a slower degradation of the degradable particulates is desired. Poly(D,L-lactide) may be a more amorphous polymer with a resultant faster hydrolysis rate. The use of poly(D,L-lactide) may be suitable for other applications where a more rapid degradation may be appropriate. The stereoisomers of lactic acid may be used individually or combined to be used in accordance with embodiments of the present invention. Additionally, they may be copolymerized with, for example, glycolide or other monomers like ε-caprolactone, 1,5-dioxepan-2-one, trimethylene carbonate, or other suitable monomers to obtain polymers with different properties or degradation times. Additionally, the lactic acid stereoisomers can be modified to be used in embodiments of the present invention by, inter alia, blending, copolymerizing or otherwise mixing the stereoisomers, blending, copolymerizing or otherwise mixing high and low molecular weight poly(lactides), or by blending, copolymerizing or otherwise mixing a poly(lactic acid) with another polyester or polyesters.


Plasticizers may be used in embodiments of the aliphatic polyesters of the present invention. The plasticizers may be present in an amount sufficient to provide the desired characteristics, for example, (a) more effective compatibilization of the melt blend components, (b) improved processing characteristics during the blending and processing steps, and (c) control and regulation of the sensitivity and degradation of the polymer by moisture. Suitable plasticizers include, but are not limited to, derivatives of oligomeric lactic acid, selected from the group defined by the formula:




embedded image



where R is a hydrogen, alkyl, aryl, alkylaryl, acetyl, heteroatom, or a mixture thereof and R is saturated, where R′ is a hydrogen, alkyl, aryl, alkylaryl, acetyl, heteroatom, or a mixture thereof and R′ is saturated, where R and R′ cannot both be hydrogen, where q is an integer: 2≦q≦75; and mixtures thereof. In certain exemplary embodiments, q is an integer: 2≦q≦10. As used herein, the term “derivatives of oligomeric lactic acid” includes derivatives of oligomeric lactide.


The physical properties of aliphatic polyesters depend on several factors, including, inter alia, the composition of the repeat units, flexibility of the chain, presence of polar groups, molecular mass, degree of branching, crystallinity, and orientation. For example, short-chain branches reduce the degree of crystallinity of polymers while long-chain branches lower the melt viscosity and impart, inter alia, elongational viscosity with tension-stiffening behavior. The properties of the material utilized further can be tailored by blending, and copolymerizing it with another polymer, or by changing the macromolecular architecture (e.g., hyper-branched polymers, star-shaped, or dendrimers, etc.). The properties of any such suitable aliphatic polyesters (e.g., hydrophobicity, hydrophilicity, rate of degradation, etc.) can be tailored by introducing select functional groups along the polymer chains. For example, poly(phenyllactide) will degrade at about ⅕th of the rate of racemic poly(lactide) at a pH of 7.4 at 55° C. One of ordinary skill in the art, with the benefit of this disclosure, will be able to determine the appropriate functional groups to introduce to the polymer chains to achieve the desired physical properties of the aliphatic polyesters.


By way of example and not limitation, certain crosslinked aliphatic polyesters may be prepared via a two-step process that includes polymerizing and/or functionalizing an aliphatic polyester to form a functionalized aliphatic polyester and crosslinking the molecules of the functionalized aliphatic polyester. Examples of processes that may be used to prepare crosslinked aliphatic polyesters that may be suitable for use in embodiments of the present invention are described in an article entitled “Structure Modification and Crosslinking of Methacrylated Polylactide Oligomers” by Antti O. Helminen et al. in The Journal of Applied Polymer Science, Vol. 86, pages 3616-3624 (2002), and WIPO Patent Application Publication No. WO 2006/053936 by Jukka Seppälä, the relevant disclosures of which are herein incorporated by reference.


For example, a degradable aliphatic polyester may be polymerized to include different numbers of hydroxyl functional groups, or an existing aliphatic polyester may be functionalized with different numbers of hydroxyl functional groups, to form a functionalized aliphatic polyester having one or more carbon-carbon double bonds. These functional groups may be provided via reaction of the aliphatic polyester with a functionalizing agent that may comprise one or more diols, polyfunctional alcohols, dicarboxylic acids, polyfunctional carboxylic acids, anhydrides, derivatives thereof, and combinations thereof. The choice of a particular functionalizing agent used may depend on several factors that will be recognized by a person of ordinary skill in the art with the benefit of this disclosure, including, but not limited to, the molecular structure and/or size of the functionalized aliphatic polyester desired. After at least one functionalized aliphatic polyester is generated, a crosslinking initiator and/or energy source may be used to form a radical at the double-bond site, and these radicals formed on different molecules of the functionalized aliphatic polyester may interact with each other so as to form one or more crosslinks between them. The crosslinking initiator may comprise any substance that is capable of forming a radical on the functionalized aliphatic polyester. Examples of suitable crosslinking initiators may include organic peroxy compounds (e.g., diazyl peroxides, peroxy esters, peroxy dicarbonates, monoperoxy carbonates, diperoxy ketals, dialkyl peroxides, sulfonyl peroxides, ketone peroxides, and peroxy carboxylic acids), inorganic peroxides (e.g., hydrogen peroxide, oxygen, ozone, and azo compounds), redox initiators, derivatives thereof, and combinations thereof. Suitable energy sources may comprise a heat source, a light source, a radiation source, and combinations thereof. The energy sources suitable for use in embodiments of the present invention may vary by numerous different properties and settings, including but not limited to, wavelength of light produced, intensity of light produced, amount of heat produced, and the like. In certain embodiments, the light source may comprise an instrument that is capable of emitting blue light (e.g., light having a wavelength of about 400 nm to about 500 nm).


In certain embodiments of the present invention where this method of preparing the crosslinked aliphatic polyester is used, the crosslinking initiator may be formulated to remain inactive until it is “activated” by, among other things, certain conditions in the fluid (e.g., pH, temperature, etc.) and/or contact with some other substance. In some embodiments, the crosslinking initiator may be delayed, for example, by encapsulation with a coating that delays its release until a desired time or place. A degradable polymer or a fatty acid may be used as the coating. The choice of a particular crosslinking initiator and/or energy source will be governed by several considerations that will be recognized by one skilled in the art, including but not limited to the following: the type of functionalized aliphatic polyester included, the molecular weight of the functionalized aliphatic polyester, the pH of the treatment fluid, temperature, and/or the desired time at which to crosslink the aliphatic polyester. The exact type and amount of crosslinking initiator and/or the particular parameters of the energy source used depends upon the specific aliphatic polyester to be crosslinked, formation temperature conditions, and other factors recognized by those individuals skilled in the art, with the benefit of this disclosure.


Optionally, a crosslinking accelerator may be used, inter alia, to increase the rate at which the functionalized aliphatic polyesters form crosslinks. Examples of suitable crosslinking accelerators that may be used include, but are not limited to, metal compounds (e.g., cobalt compounds), organic amines, and the like. The choice of whether to use a crosslinking accelerator, and, if used, the exact type and amount of the crosslinking accelerator is within the ability of those individuals skilled in the art, with the benefit of this disclosure.


In certain embodiments, the solid particles used in the treatment fluids of the present invention may comprise a degradable aliphatic polyester and a hydrated organic or inorganic compound. Examples of such hydrated organic or inorganic compounds include, but are not limited to, sodium acetate trihydrate, L-tartaric acid disodium salt dihydrate, sodium citrate dihydrate, sodium tetraborate decahydrate, sodium hydrogen phosphate heptahydrate, sodium phosphate dodecahydrate, amylose, starch-based hydrophilic polymers, or cellulose-based hydrophilic polymers. In certain exemplary embodiments, the degradable aliphatic polyester is poly(lactic acid). In certain exemplary embodiments, the hydrated organic or inorganic compound is sodium acetate trihydrate. In certain exemplary embodiments, the lactide units of the aliphatic polyester and releasable water from the hydrated organic or inorganic compound may be present in stoichiometric amounts. In certain exemplary embodiments, the bridging agent comprises a degradable aliphatic polyester and a hydrated organic or inorganic compound in combination with a bridging agent that comprises calcium carbonate in an amount in the range of about 1 pound to about 100 pounds of calcium carbonate per barrel of treatment fluid.


In some embodiments, the treatment fluids of the present invention may further comprise a viscosifier. Viscosifiers suitable for use in embodiments of the present invention include, but are not limited to, biopolymers (e.g., xanthan, succinoglycan, and diutan), clarified biolpolymers, cellulose, cellulose derivatives (e.g., hydroxyethylcellulose), guar, and guar derivatives (e.g., hydroxypropyl guar). Commercially available examples of suitable viscosifiers include, but are not limited to, those that are available from Halliburton Energy Services, Inc., of Duncan, Okla., under the trade name “WG-37” and “N-VIS™.” Suitable viscosifiers may also include an organophilic clay, a synthetic oil-soluble polymer, or a polymeric fatty acid. An example of a synthetic oil-soluble polymer is commercially available from Halliburton Energy Services, Inc., of Houston, Tex., under the trade name “BARAPAK®.” An example of a polymeric fatty acid is commercially available from Halliburton Energy Services, Inc., of Houston, Tex., under the trade name “X-VIS™.”


In certain embodiments, a viscosifier should be included in the degradable polymer composition in an amount sufficient to provide a desired degree of solids suspension or viscosity. In some embodiments, a viscosifier may be included in the degradable polymer composition in an amount in the range of about 0.001% to about 2% by volume. In other embodiments, a viscosifier may be included in the degradable polymer composition in an amount in the range of about 0.001% to about 1% by volume.


In some embodiments, the treatment fluids of the present invention may further comprise a fluid loss control additive. Generally, any fluid loss control additive may be suitable for use in the treatment fluids of the present invention. Examples of suitable fluid loss control additives include, but are not limited to, synthetic oil-soluble polymers, powdered hydrocarbon resins, organophilic lignite, starches, starch ether derivatives, hydroxyethylcellulose, cross-linked hydroxyethylcellulose, and combinations thereof. An example of a synthetic oil-soluble polymer is commercially available from Halliburton Energy Services, Inc., of Houston, Tex., under the trade name “BARAPAK®.” In certain exemplary embodiments, the fluid loss control additive may be a synthetic oil-soluble copolymer commercially available from Halliburton Energy Services, Inc., under the trade name “ADAPTA™.”


In some embodiments, the fluid loss control additive may be present in the treatment fluids of the present invention in an amount sufficient to provide a desired degree of fluid loss control. In certain embodiments, the fluid loss control additive may be present in the treatment fluids in an amount in the range of about 0.01% to about 5% by weight. In some embodiments, the fluid loss control additive is present in the subterranean treatment fluid in an amount in the range of about 1% to about 2% by weight.


In accordance with embodiments of the present invention, the treatment fluids of the present invention that comprise a crosslinked aliphatic polyester may be used in any of a variety of suitable applications. By way of example, the crosslinked aliphatic polyesters may be used in subterranean applications, including, but not limited to, drilling, completion, stimulation, and workover operations. Among other things, the crosslinked aliphatic polyesters may be used in subterranean operations as fluid loss control additives, diverting agents, bridging agents, drilling fluid additives, cement additives, and the like. An example method of the present invention generally may comprise providing a treatment fluid comprising a carrier fluid and a solid particle that comprises a crosslinked aliphatic polyester; and introducing the treatment fluid into a well bore having a bottom hole circulating temperature of at least about 300° F. In certain embodiments, the method further may comprise allowing the crosslinked aliphatic polyester to degrade thereby releasing an acid. In certain embodiments, the acid released during hydrolysis of the crosslinked aliphatic polyester may be utilized in a well bore application, such as to facilitate a reduction in viscosity of a fluid or to degrade a filter cake, as well as for numerous other functions in subterranean operations.


Embodiments of the present invention may include using the crosslinked aliphatic polyesters as a bridging agent. An example of a method of the present invention comprises the steps of: placing a treatment fluid in a subterranean formation, the treatment fluid comprising a carrier fluid and a solid particle comprising the aliphatic polyester. The treatment fluid may further comprise a viscosifier and a fluid loss control additive. In certain embodiments, the treatment fluid may be used as a drilling fluid, in that the treatment fluid may be circulated in a well bore while drilling. In certain embodiments, the method may include forming a filter cake comprising the solid particle upon a surface. Fluid loss to the formation through the filter cake may be reduced. As the filter cake comprises the aliphatic polyester, the filter cake may be “self degrading,” in accordance with embodiments of the present invention, in that the filter cake may be removed without assistance of a separate “clean up” solution or “breaker” through the well bore. Though the filter cake formed by the treatment fluids in accordance with embodiments of the present invention may be self degrading, an operator nevertheless occasionally may elect to circulate a separate clean-up solution or breaker through the well bore under certain circumstances, to enhance the rate of degradation of the filter cake. By way of example, removal of the filter cake may be enhanced by contacting the filter cake with water.


Another example of a method of the present invention comprises a method of degrading a filter cake in a subterranean formation, the filter cake having been deposited therein by a treatment fluid comprising a bridging agent, comprising the step of utilizing a bridging agent comprising a degradable material comprising a crosslinked aliphatic polyester. Another example of a method of the present invention comprises a method of drilling an open hole in a subterranean formation, comprising the steps of: circulating through a drill pipe and drill bit a treatment fluid comprising a viscosified fluid, a fluid loss control additive, and a bridging agent comprising a degradable material comprising a crosslinked aliphatic polyester; forming a filter cake comprising the bridging agent upon a surface within the formation; and permitting the filter cake to degrade. The filter cake formed by the treatment fluids of the present invention is removed after a desired amount of time by being contacted with a degrading agent. In certain embodiments, the degrading agent comprises water. The source of the degrading agent may be, inter alia, a treatment fluid, such as a gravel pack fluid or a completion brine, for instance. In certain embodiments, the source of the degrading agent may be the bridging agent itself. For example, the bridging agent may comprise a water-containing compound. Any compound containing releasable water may be used as the water-containing compound. As referred to herein, the term “releasable water” will be understood to mean water that may be released under desired downhole conditions, including, inter alia, temperature. In certain embodiments, the water-containing compound may be sodium acetate trihydrate, sodium borate decahydrate, sodium carbonate decahydrate, or the like. In certain preferred embodiments, the water-containing compound is sodium acetate trihydrate.


Embodiments of the present invention may include using the crosslinked aliphatic polyester as a diverting agent. In one embodiment, the present invention provides a method comprising: providing a treatment fluid; adding to the treatment fluid a diverting agent comprising a solid particle comprising a crosslinked aliphatic polyester; and placing the treatment fluid into a portion of subterranean formation. The solid particle comprising the crosslinked aliphatic polymer may the divert treatment fluids introduced into the treated portion of the subterranean formation.


Embodiments of the present invention may include using the crosslinked aliphatic polyester as a fluid loss control particle. In one embodiment, the present invention provides a method of providing fluid loss control comprising: providing a treatment fluid comprising a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester; and placing the treatment fluid into a well bore that penetrates subterranean formation. The presence of the solid particle comprising the crosslinked aliphatic polyester in the treatment fluid may reduce the loss of fluid from the treatment fluid into the subterranean formation.


Embodiments of the present invention may include using the crosslinked aliphatic polyesters to generate an acid downhole. In one embodiment, the present invention provides a method comprising: providing a treatment fluid that comprises a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester; placing the treatment fluid into a subterranean formation; and allowing an acid to generate from the crosslinked aliphatic polyester. As will be appreciated by those of ordinary skill in the art, with the benefit of this disclosure, the crosslinked aliphatic polyester should undergo degradation and degrade downhole to release an acid. The term “degradation” refers to both the two relatively extreme cases of hydrolytic degradation that the crosslinked aliphatic polyester may undergo, e.g., bulk erosion and surface erosion, and any stage of degradation in between these two. This degradation can be a result of, inter alia, a chemical or thermal reaction, or a reaction induced by radiation.


Embodiments of the present invention may include using the crosslinked aliphatic polyesters to degrade a filter cake. In one embodiment, the present invention provides a method of degrading a filter cake comprising: introducing a treatment fluid that comprises a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester into the subterranean formation; allowing the crosslinked aliphatic polyester to generate an acid; allowing the acid to degrade at least a portion of the filter cake.


Embodiments of the present invention may include using the crosslinked aliphatic polyesters to facilitate a reduction of viscosity of a fluid. In one embodiment, the present invention provides a method comprising: providing a servicing fluid having a viscosity and comprising a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester. In certain embodiments, to provide the servicing fluid with an increased viscosity, the servicing fluid may comprise a gelling agent and/or a crosslinking agent. The method may comprise introducing the servicing fluid into a subterranean formation. The method may comprise allowing the crosslinked aliphatic polyester to release an acid, thereby reducing the viscosity of the servicing fluid. The acid released by the crosslinked aliphatic polyester may reduce the viscosity of the servicing fluid, in certain embodiments, due to a pH reduction. One should note that the conditions of the fluid, e.g., the basicity or acidity of the fluid, will affect the hydrolysis of the crosslinked aliphatic polyester.


Embodiments of the present invention may include using the crosslinked aliphatic polyesters as a cement additive. An example of a method of the present invention is a method that comprises: providing a cement composition that comprises hydraulic cement, a solid particle comprising a crosslinked aliphatic polyester, and water; placing the cement composition in a subterranean formation, allowing the cement composition to set therein. The method may comprise allowing the crosslinked aliphatic polyester to release an acid.


Embodiments of the present invention may include using the crosslinked aliphatic polyester as a biodegradable downhole tool. In one embodiment, the present invention is directed to a disposable downhole tool comprising a crosslinked aliphatic polyester. The biodegradable downhole tool may comprise a plug that is used in a well stimulation/fracturing operation, commonly known as a “frac plug.” A frac plug is a temporary plug that substantially blocks off permeable zones to prevent loss of fluid into those permeable zones or to protect those zones from damage during a well stimulation/fracturing operation. Examples of suitable biodegradable downhole tools are described in U.S. Pat. No. 7,093,664, the entirety of which is hereby incorporated by reference.


Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present invention. In particular, every range of values (of the form, “about a to about b,” or, equivalently, “approximately a to b,” or, equivalently, “approximately a-b”) disclosed herein is to be understood as referring to the power set (the set of all subsets) of the respective range of values, and set forth every range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee.

Claims
  • 1. A method comprising: providing a treatment fluid comprising a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester; andplacing the treatment fluid into a subterranean formation.
  • 2. The method of claim 1 comprising allowing the crosslinked aliphatic polyester to release an acid.
  • 3. The method of claim 2, wherein the acid released by the crosslinked aliphatic polyester contacts a filter cake present in the subterranean formation, such that at least a portion of the filter cake is degraded.
  • 4. The method of claim 2, wherein treatment fluid has a viscosity, and wherein the acid released by the crosslinked aliphatic polyester reduces the viscosity of the treatment fluid.
  • 5. The method of claim 1, wherein the treatment fluid comprises a fluid loss control additive.
  • 6. The method of claim 5, wherein the fluid loss control additive is present in the treatment fluid in an amount in the range of from about 0.01% to about 5% by weight of the treatment fluid.
  • 7. The method of claim 1, wherein the carrier fluid comprises at least one fluid selected from the group consisting of: an aqueous based fluid, a nonaqueous based fluid, and a mixture thereof.
  • 8. The method of claim 1, wherein the carrier fluid is present in an amount in the range of from about 20% to about 99% by weight of the treatment fluid.
  • 9. The method of claim 1, wherein the solid particle is present in an amount in the range of from about 0.1% to about 32% by weight of the treatment fluid.
  • 10. The method of claim 1, wherein the solid particle has a particle size distribution in the range of from about 0.1 microns to about 1.0 millimeters.
  • 11. The method of claim 1, wherein the solid particle comprises crosslinked poly(lactic acid).
  • 12. The method of claim 1, wherein the solid particle comprises a hydrated organic or inorganic compound.
  • 13. The method of claim 1, wherein in the treatment fluid comprises a viscosifier.
  • 14. A method comprising: placing a treatment fluid in a subterranean formation, the treatment fluid comprising: a carrier fluid;a viscosifier;a fluid loss control additive; anda bridging agent comprising a crosslinked aliphatic polyester; andforming a filter cake comprising the bridging agent upon a surface within the subterranean formation whereby fluid loss to the subterranean formation through the filter cake is reduced.
  • 15. The method of claim 14 further comprising contacting the filter cake with a clean-up solution or breaker.
  • 16. The method of claim 15 wherein the clean-up solution comprises water.
  • 17. The method of claim 14, wherein the bridging agent comprises crosslinked poly(lactic acid).
  • 18. The method of claim 14, wherein the treatment fluid comprises a drilling fluid.
  • 19. The method of claim 14, wherein the filter cake is self degrading.
  • 20. A treatment fluid comprising a carrier fluid and a solid particle comprising a crosslinked aliphatic polyester.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 11/634,320, entitled “Improved Treatment Fluids and Methods of Forming Degradable Filter Cakes and Their Use in Subterranean Formations,” filed Dec. 5, 2006 now U.S. Pat. No. 7,674,753, which is a continuation-in-part of U.S. patent application Ser. No. 10/832,163, entitled “Improved Treatment Fluids and Methods of Use in Subterranean Formations,” filed Apr. 26, 2004 now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 10/664,126 entitled “Improved Subterranean Treatment Fluids and Methods of Treating Subterranean Formations,” filed Sep. 17, 2003, incorporated by reference herein for all purposes, and from which priority is claimed pursuant to 35 U.S.C. §120.

US Referenced Citations (402)
Number Name Date Kind
2005183 Flemming Jun 1935 A
2238671 Woodhouse Apr 1941 A
2703316 Palmer Mar 1955 A
3173484 Huitt et al. Mar 1965 A
3195635 Fast Jul 1965 A
3272650 MacVittie Sep 1966 A
3302719 Fischer Feb 1967 A
3364995 Atkins et al. Jan 1968 A
3366178 Malone et al. Jan 1968 A
3455390 Gallus Jul 1969 A
3784585 Schmitt et al. Jan 1974 A
3819525 Hattenbrun Jun 1974 A
3828854 Templeton et al. Aug 1974 A
3836465 Rhudy et al. Sep 1974 A
3868998 Lybarger et al. Mar 1975 A
3912692 Casey et al. Oct 1975 A
3948672 Harnsberger Apr 1976 A
3955993 Curtice May 1976 A
3960736 Free et al. Jun 1976 A
3968840 Tate Jul 1976 A
3986355 Klaeger Oct 1976 A
3998272 Maly Dec 1976 A
3998744 Arnold et al. Dec 1976 A
4010071 Colegrove Mar 1977 A
4068718 Cooke, Jr. et al. Jan 1978 A
4169798 DeMartino Oct 1979 A
4172066 Zweigle et al. Oct 1979 A
4261421 Watanabe Apr 1981 A
4265673 Pace et al. May 1981 A
4267887 Watanabe May 1981 A
4299825 Lee Nov 1981 A
4387769 Erbstoesser et al. Jun 1983 A
4460052 Gockel Jul 1984 A
4470915 Conway Sep 1984 A
4498995 Gockel Feb 1985 A
4502540 Byham Mar 1985 A
4506734 Nolte Mar 1985 A
4521316 Sikorski Jun 1985 A
4526695 Erbstoesser et al. Jul 1985 A
4632876 Laird et al. Dec 1986 A
4694905 Armbruster Sep 1987 A
4715967 Bellis Dec 1987 A
4716964 Erbstoesser et al. Jan 1988 A
4767706 Levesque Aug 1988 A
4772346 Anderson et al. Sep 1988 A
4785884 Armbruster Nov 1988 A
4793416 Mitchell Dec 1988 A
4797262 Dewitz Jan 1989 A
4809783 Hollenbeck et al. Mar 1989 A
4817721 Pober Apr 1989 A
4822500 Dobson, Jr. et al. Apr 1989 A
4829100 Murphey et al. May 1989 A
4836940 Alexander Jun 1989 A
4843118 Lai et al. Jun 1989 A
4848467 Cantu et al. Jul 1989 A
4863980 Cowan et al. Sep 1989 A
4886354 Welch et al. Dec 1989 A
4894231 Moreau et al. Jan 1990 A
4957165 Cantu et al. Sep 1990 A
4961466 Himes et al. Oct 1990 A
4986353 Clark et al. Jan 1991 A
4986354 Cantu et al. Jan 1991 A
4986355 Casad et al. Jan 1991 A
5034139 Reid et al. Jul 1991 A
5082056 Tackett, Jr. Jan 1992 A
5142023 Gruber et al. Aug 1992 A
5152781 Tang et al. Oct 1992 A
5161615 Hutchins et al. Nov 1992 A
5203834 Hutchins et al. Apr 1993 A
5213446 Dovan May 1993 A
5216050 Sinclair Jun 1993 A
5247059 Gruber et al. Sep 1993 A
5249628 Surjaatmadja Oct 1993 A
5251697 Shuler Oct 1993 A
5295542 Cole et al. Mar 1994 A
5304620 Holtmyer et al. Apr 1994 A
5314031 Hale et al. May 1994 A
5325923 Surjaatmadja et al. Jul 1994 A
5330005 Card et al. Jul 1994 A
5359026 Gruber Oct 1994 A
5360068 Sprunt et al. Nov 1994 A
5363916 Himes et al. Nov 1994 A
5373901 Norman et al. Dec 1994 A
5386874 Laramay et al. Feb 1995 A
5396957 Surjaatmadja et al. Mar 1995 A
5402846 Jennings, Jr. et al. Apr 1995 A
5439055 Card et al. Aug 1995 A
5460226 Lawton et al. Oct 1995 A
5464060 Hale et al. Nov 1995 A
5475080 Gruber et al. Dec 1995 A
5484881 Gruber et al. Jan 1996 A
5487897 Polson et al. Jan 1996 A
5492177 Yeh et al. Feb 1996 A
5496557 Feijen et al. Mar 1996 A
5497830 Boles et al. Mar 1996 A
5499678 Surjaatmadja et al. Mar 1996 A
5501276 Weaver et al. Mar 1996 A
5505787 Yamaguchi Apr 1996 A
5512071 Yam et al. Apr 1996 A
5536807 Gruber et al. Jul 1996 A
5555936 Pirri et al. Sep 1996 A
5566310 Chan Oct 1996 A
5591700 Harris et al. Jan 1997 A
5594095 Gruber et al. Jan 1997 A
5602083 Gabrysch et al. Feb 1997 A
5604186 Hunt et al. Feb 1997 A
5607905 Dobson, Jr. et al. Mar 1997 A
5613558 Dillenbeck Mar 1997 A
5670473 Scepanski Sep 1997 A
5697440 Weaver et al. Dec 1997 A
5698322 Tsai et al. Dec 1997 A
5723416 Liao Mar 1998 A
5765642 Surjaatmadja Jun 1998 A
5783527 Dobson, Jr. et al. Jul 1998 A
5791415 Nguyen et al. Aug 1998 A
5799734 Normal et al. Sep 1998 A
5833000 Weaver et al. Nov 1998 A
5849401 El-Afandi et al. Dec 1998 A
5853048 Weaver et al. Dec 1998 A
5888944 Patel Mar 1999 A
5893416 Read Apr 1999 A
5908073 Nguyen et al. Jun 1999 A
5916849 House Jun 1999 A
5924488 Nguyen et al. Jul 1999 A
5964291 Bourne et al. Oct 1999 A
5977030 House Nov 1999 A
5979557 Card et al. Nov 1999 A
5981447 Chang Nov 1999 A
5996693 Heathman Dec 1999 A
6004400 Bishop et al. Dec 1999 A
6024170 McCabe et al. Feb 2000 A
6028113 Scepanski Feb 2000 A
6047772 Weaver et al. Apr 2000 A
6110875 Tjon-Joe-Pin et al. Aug 2000 A
6114410 Betzold Sep 2000 A
6123159 Brookey et al. Sep 2000 A
6123965 Jacob et al. Sep 2000 A
6131661 Conner et al. Oct 2000 A
6135987 Tsai et al. Oct 2000 A
6143698 Murphey et al. Nov 2000 A
6148917 Brookey et al. Nov 2000 A
6162766 Muir et al. Dec 2000 A
6169058 Le et al. Jan 2001 B1
6172011 Card et al. Jan 2001 B1
6189615 Sydansk Feb 2001 B1
6202751 Chatterji et al. Mar 2001 B1
6209643 Nguyen et al. Apr 2001 B1
6209646 Reddy et al. Apr 2001 B1
6214773 Harris et al. Apr 2001 B1
6242390 Mitchell et al. Jun 2001 B1
6258755 House Jul 2001 B1
6260622 Blok et al. Jul 2001 B1
6291013 Gibson et al. Sep 2001 B1
6300286 Dobson, Jr. et al. Oct 2001 B1
6302209 Thompson et al. Oct 2001 B1
6308788 Patel et al. Oct 2001 B1
6311773 Todd et al. Nov 2001 B1
6323307 Bigg et al. Nov 2001 B1
6326458 Gruber et al. Dec 2001 B1
6328105 Betzold Dec 2001 B1
6330917 Chatterji et al. Dec 2001 B2
6357527 Norman et al. Mar 2002 B1
6364945 Chatterji et al. Apr 2002 B1
6380138 Ischy et al. Apr 2002 B1
6387986 Moradi-Araghi et al. May 2002 B1
6390195 Nguyen et al. May 2002 B1
6394185 Constien May 2002 B1
6422314 Todd et al. Jul 2002 B1
6422326 Brookey et al. Jul 2002 B1
6432155 Swazey et al. Aug 2002 B1
6454003 Chang et al. Sep 2002 B1
6485947 Rajgarhia et al. Nov 2002 B1
6488763 Brothers et al. Dec 2002 B2
6494263 Todd Dec 2002 B2
6508305 Brannon et al. Jan 2003 B1
6509301 Vollmer et al. Jan 2003 B1
6527051 Reddy et al. Mar 2003 B1
6554071 Reddy et al. Apr 2003 B1
6566310 Chan May 2003 B2
6569814 Brady et al. May 2003 B1
6578630 Simpson et al. Jun 2003 B2
6586372 Bradbury Jul 2003 B1
6599863 Palmer et al. Jul 2003 B1
6667279 Hessert et al. Dec 2003 B1
6669771 Tokiwa et al. Dec 2003 B2
6681856 Chatterji et al. Jan 2004 B1
6686328 Binder Feb 2004 B1
6691780 Nguyen et al. Feb 2004 B2
6702023 Harris et al. Mar 2004 B1
6702044 Reddy Mar 2004 B2
6710019 Sawdon et al. Mar 2004 B1
6716797 Brookey Apr 2004 B2
6737385 Todd et al. May 2004 B2
6761218 Nguyen et al. Jul 2004 B2
6763888 Harris et al. Jul 2004 B1
6764981 Eoff et al. Jul 2004 B1
6770293 Angel et al. Aug 2004 B2
6793018 Dawson et al. Sep 2004 B2
6793730 Reddy et al. Sep 2004 B2
6806235 Mueller et al. Oct 2004 B1
6817414 Lee Nov 2004 B2
6818594 Freeman et al. Nov 2004 B1
6828280 England et al. Dec 2004 B2
6837309 Boney et al. Jan 2005 B2
6840318 Lee et al. Jan 2005 B2
6852173 Banerjee et al. Feb 2005 B2
6861394 Ballard et al. Mar 2005 B2
6877563 Todd et al. Apr 2005 B2
6883608 Parlar et al. Apr 2005 B2
6886635 Hossaini et al. May 2005 B2
6896058 Munoz, Jr. et al. May 2005 B2
6904971 Brothers et al. Jun 2005 B2
6949491 Cooke, Jr. Sep 2005 B2
6953090 Vijn et al. Oct 2005 B2
6959767 Horton et al. Nov 2005 B2
6978838 Parlar et al. Dec 2005 B2
6981552 Reddy et al. Jan 2006 B2
6983798 Todd Jan 2006 B2
6983801 Dawson et al. Jan 2006 B2
6987083 Phillippi et al. Jan 2006 B2
6997259 Nguyen Feb 2006 B2
7000701 Todd et al. Feb 2006 B2
7007752 Reddy et al. Mar 2006 B2
7021377 Todd et al. Apr 2006 B2
7032663 Nguyen Apr 2006 B2
7033976 Guzman Apr 2006 B2
7036586 Roddy et al. May 2006 B2
7036587 Munoz, Jr. et al. May 2006 B2
7044220 Nguyen et al. May 2006 B2
7044224 Nguyen May 2006 B2
7049272 Sinclair et al. May 2006 B2
7063151 Nguyen et al. Jun 2006 B2
7066258 Justus et al. Jun 2006 B2
7066260 Sullivan et al. Jun 2006 B2
7069994 Cooke, Jr. Jul 2006 B2
7080688 Todd et al. Jul 2006 B2
7093658 Chatterji et al. Aug 2006 B2
7093664 Todd et al. Aug 2006 B2
7096947 Todd et al. Aug 2006 B2
7101829 Guichard et al. Sep 2006 B2
7131491 Blauch et al. Nov 2006 B2
7132389 Lee Nov 2006 B2
7140438 Frost et al. Nov 2006 B2
7147067 Getzlaf et al. Dec 2006 B2
7151077 Prud'homme et al. Dec 2006 B2
7153902 Altes et al. Dec 2006 B2
7156174 Roddy et al. Jan 2007 B2
7165617 Lord et al. Jan 2007 B2
7166560 Still et al. Jan 2007 B2
7168489 Frost et al. Jan 2007 B2
7172022 Reddy et al. Feb 2007 B2
7178594 Patel Feb 2007 B2
7178596 Blauch et al. Feb 2007 B2
7195068 Todd Mar 2007 B2
7204311 Welton et al. Apr 2007 B2
7204312 Roddy et al. Apr 2007 B2
7205264 Boles Apr 2007 B2
7216705 Saini et al. May 2007 B2
7219731 Sullivan May 2007 B2
7228904 Todd et al. Jun 2007 B2
7256159 Guichard et al. Aug 2007 B2
7261156 Nguyen et al. Aug 2007 B2
7264051 Nguyen et al. Sep 2007 B2
7265079 Wilbert et al. Sep 2007 B2
7267170 Mang et al. Sep 2007 B2
7276466 Todd et al. Oct 2007 B2
7299869 Kalman Nov 2007 B2
7299876 Lord et al. Nov 2007 B2
7303014 Reddy et al. Dec 2007 B2
7306037 Nguyen et al. Dec 2007 B2
7322412 Badalamenti et al. Jan 2008 B2
7353876 Savery et al. Apr 2008 B2
7353879 Todd et al. Apr 2008 B2
7413017 Nguyen et al. Aug 2008 B2
7419937 Rimmer et al. Sep 2008 B2
7448450 Luke et al. Nov 2008 B2
7455112 Moorehead et al. Nov 2008 B2
7461697 Todd et al. Dec 2008 B2
7475728 Pauls et al. Jan 2009 B2
7476644 Cooke, Jr. Jan 2009 B2
7484564 Welton et al. Feb 2009 B2
7497258 Savery et al. Mar 2009 B2
7497278 Schriener et al. Mar 2009 B2
7501530 Todd et al. Mar 2009 B2
7506689 Surjaatmadja et al. Mar 2009 B2
7547665 Welton et al. Jun 2009 B2
7553800 Munoz, Jr. et al. Jun 2009 B2
7595280 Welton et al. Sep 2009 B2
7598208 Todd Oct 2009 B2
7608566 Saini et al. Oct 2009 B2
7608567 Saini Oct 2009 B2
7648946 Munoz Jan 2010 B2
7662753 Saini Feb 2010 B2
20010016562 Muir et al. Aug 2001 A1
20020036088 Todd Mar 2002 A1
20020119169 Angel Aug 2002 A1
20020125012 Dawson Sep 2002 A1
20030054962 England Mar 2003 A1
20030060374 Cooke Mar 2003 A1
20030114314 Ballard Jun 2003 A1
20030130133 Vollmer Jul 2003 A1
20030147965 Bassett et al. Aug 2003 A1
20030188766 Banerjee Oct 2003 A1
20030230407 Vijn et al. Dec 2003 A1
20030234103 Lee Dec 2003 A1
20040014606 Parlar Jan 2004 A1
20040014607 Sinclair Jan 2004 A1
20040040706 Hossaini Mar 2004 A1
20040055747 Lee Mar 2004 A1
20040070093 Mathiowitz et al. Apr 2004 A1
20040094300 Sullivan May 2004 A1
20040099416 Vijn May 2004 A1
20040106525 Wilbert Jun 2004 A1
20040138068 Rimmer Jul 2004 A1
20040152601 Still Aug 2004 A1
20040152602 Boles Aug 2004 A1
20040162386 Altes Aug 2004 A1
20040170836 Bond et al. Sep 2004 A1
20040214724 Todd Oct 2004 A1
20040216876 Lee Nov 2004 A1
20040231845 Cooke, Jr. Nov 2004 A1
20040261993 Nguyen Dec 2004 A1
20040261995 Nguyen Dec 2004 A1
20040261996 Munoz Dec 2004 A1
20040261999 Nguyen Dec 2004 A1
20050006095 Justus Jan 2005 A1
20050028976 Nguyen Feb 2005 A1
20050034861 Saini et al. Feb 2005 A1
20050034865 Todd Feb 2005 A1
20050034868 Frost Feb 2005 A1
20050045328 Frost Mar 2005 A1
20050051330 Nguyen Mar 2005 A1
20050056423 Todd Mar 2005 A1
20050059556 Munoz, Jr. et al. Mar 2005 A1
20050059557 Todd et al. Mar 2005 A1
20050059558 Blanch Mar 2005 A1
20050103496 Todd May 2005 A1
20050126780 Todd Jun 2005 A1
20050126785 Todd Jun 2005 A1
20050130848 Todd et al. Jun 2005 A1
20050161220 Todd Jul 2005 A1
20050167104 Roddy Aug 2005 A1
20050167105 Roddy Aug 2005 A1
20050167107 Roddy Aug 2005 A1
20050183741 Surjaatmadja et al. Aug 2005 A1
20050205258 Reddy Sep 2005 A1
20050205265 Todd Sep 2005 A1
20050205266 Todd Sep 2005 A1
20050252659 Sullivan Nov 2005 A1
20050272613 Cooke Dec 2005 A1
20050277554 Blauch et al. Dec 2005 A1
20060016596 Pauls Jan 2006 A1
20060032633 Nguyen Feb 2006 A1
20060046938 Harris et al. Mar 2006 A1
20060048938 Kalman Mar 2006 A1
20060065397 Nguyen Mar 2006 A1
20060105917 Munoz May 2006 A1
20060105918 Munoz, Jr. et al. May 2006 A1
20060108150 Luke May 2006 A1
20060118300 Welton et al. Jun 2006 A1
20060169182 Todd et al. Aug 2006 A1
20060169183 Todd Aug 2006 A1
20060169448 Savery et al. Aug 2006 A1
20060169450 Mang et al. Aug 2006 A1
20060169452 Savery et al. Aug 2006 A1
20060169453 Savery et al. Aug 2006 A1
20060172891 Todd Aug 2006 A1
20060172893 Todd et al. Aug 2006 A1
20060172894 Mang et al. Aug 2006 A1
20060172895 Mang et al. Aug 2006 A1
20060185847 Saini Aug 2006 A1
20060185848 Surjaatmadja Aug 2006 A1
20060205608 Todd Sep 2006 A1
20060234873 Ballard Oct 2006 A1
20060243449 Welton et al. Nov 2006 A1
20060247135 Welton Nov 2006 A1
20060254774 Saini et al. Nov 2006 A1
20060258543 Saini Nov 2006 A1
20060258544 Saini Nov 2006 A1
20060276345 Todd et al. Dec 2006 A1
20060283597 Schriener Dec 2006 A1
20070042912 Welton et al. Feb 2007 A1
20070049501 Saini et al. Mar 2007 A1
20070066492 Funkhouser et al. Mar 2007 A1
20070066493 Funkhouser et al. Mar 2007 A1
20070078063 Munoz Apr 2007 A1
20070078064 Munoz et al. Apr 2007 A1
20070100029 Reddy et al. May 2007 A1
20070235190 Lord Oct 2007 A1
20070238623 Saini et al. Oct 2007 A1
20070281868 Pauls et al. Dec 2007 A1
20070298977 Mang et al. Dec 2007 A1
20080009423 Mang et al. Jan 2008 A1
20080026955 Munoz et al. Jan 2008 A1
20080026959 Munoz et al. Jan 2008 A1
20080026960 Munoz et al. Jan 2008 A1
20080027157 Munoz et al. Jan 2008 A1
20080070810 Mang et al. Mar 2008 A1
20080139415 Todd et al. Jun 2008 A1
20080169102 Carbajal et al. Jul 2008 A1
20090062157 Munoz et al. Mar 2009 A1
20090258798 Munoz Oct 2009 A1
Foreign Referenced Citations (25)
Number Date Country
0 510 762 Oct 1992 EP
0 879 935 Nov 1998 EP
0 879 935 Feb 1999 EP
1 413 710 Apr 2004 EP
2 412 389 Mar 2004 GB
2004181820 Jul 2004 JP
WO 9315127 Aug 1993 WO
WO 9407949 Apr 1994 WO
WO 9408078 Apr 1994 WO
WO 9408090 Apr 1994 WO
WO 9509879 Apr 1995 WO
WO 9711845 Apr 1997 WO
WO 9927229 Jun 1999 WO
WO 0057022 Sep 2000 WO
WO 0102698 Jan 2001 WO
WO 0187797 Nov 2001 WO
WO 0194744 Dec 2001 WO
WO 0255843 Jan 2002 WO
WO 0212674 Feb 2002 WO
WO 03027431 Apr 2003 WO
WO 03027431 Apr 2003 WO
WO 2004007905 Jan 2004 WO
WO 2004037946 May 2004 WO
WO 2004038176 May 2004 WO
06053936 May 2006 WO
Related Publications (1)
Number Date Country
20090258798 A1 Oct 2009 US
Continuation in Parts (3)
Number Date Country
Parent 11634320 Dec 2006 US
Child 12456538 US
Parent 10832163 Apr 2004 US
Child 11634320 US
Parent 10664126 Sep 2003 US
Child 10832163 US